TR200200201T2 - İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler. - Google Patents

İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler.

Info

Publication number
TR200200201T2
TR200200201T2 TR2002/00201T TR200200201T TR200200201T2 TR 200200201 T2 TR200200201 T2 TR 200200201T2 TR 2002/00201 T TR2002/00201 T TR 2002/00201T TR 200200201 T TR200200201 T TR 200200201T TR 200200201 T2 TR200200201 T2 TR 200200201T2
Authority
TR
Turkey
Prior art keywords
oligonucleotides
human
inhibition
expression
oligonucleotide
Prior art date
Application number
TR2002/00201T
Other languages
English (en)
Inventor
Uhlmann Eugen
Greiner Beate
Unger Eberhard
Gothe Gislinde
Schwerdel Marc
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TR200200201T2 publication Critical patent/TR200200201T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bu mevcut bulus, bir insan eg5'inin belirli bir parçasi yada buradan mutasyona ugramis sekilde kodlayici nükleik asit sekansina uyan bir sekans bulundurumasi ile tanimlanan bir oligonükleotit yada bunun derivatlarindan birisi ile ilgilidir; ayrica bulus, oligonükleotit imalatina dair bir metot ve bunun kullanimini kapsar.
TR2002/00201T 1999-07-28 2000-07-21 İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler. TR200200201T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19935303A DE19935303A1 (de) 1999-07-28 1999-07-28 Oligonukleotide zur Inhibierung der Expression von humanem eg5

Publications (1)

Publication Number Publication Date
TR200200201T2 true TR200200201T2 (tr) 2002-05-21

Family

ID=7916259

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00201T TR200200201T2 (tr) 1999-07-28 2000-07-21 İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler.

Country Status (26)

Country Link
US (1) US6472521B1 (tr)
EP (1) EP1204742A2 (tr)
JP (1) JP2003505080A (tr)
KR (1) KR20020033744A (tr)
CN (1) CN1165617C (tr)
AR (1) AR024953A1 (tr)
AU (1) AU6568200A (tr)
BR (1) BR0013180A (tr)
CA (1) CA2380192A1 (tr)
CZ (1) CZ2002324A3 (tr)
DE (1) DE19935303A1 (tr)
EE (1) EE200200044A (tr)
HK (1) HK1048337B (tr)
HR (1) HRP20020075A2 (tr)
HU (1) HUP0202794A3 (tr)
IL (1) IL147541A0 (tr)
MX (1) MXPA02000817A (tr)
NO (1) NO20020365L (tr)
NZ (1) NZ516839A (tr)
PL (1) PL353733A1 (tr)
RU (1) RU2249458C2 (tr)
SK (1) SK1162002A3 (tr)
TR (1) TR200200201T2 (tr)
WO (1) WO2001007602A2 (tr)
YU (1) YU91901A (tr)
ZA (1) ZA200200655B (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6440686B1 (en) 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7199107B2 (en) * 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7163927B2 (en) * 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
JP2006521794A (ja) * 2003-02-14 2006-09-28 スミスクライン・ビーチャム・コーポレイション Ｋｓｐ発現と相関関係にある示差発現核酸
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
US7700573B2 (en) * 2004-03-23 2010-04-20 Oncotherapy Science, Inc. Method for diagnosing non-small lung cancer
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
NZ571568A (en) * 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
RU2568579C2 (ru) * 2006-05-26 2015-11-20 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Введение противосвертывающей системы reg1
CA2704853C (en) * 2007-11-06 2017-08-15 Eugen Uhlmann Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
DE102010007562A1 (de) * 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
DK2992098T3 (da) * 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
KR102365486B1 (ko) * 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 프리칼리크레인 (pkk) 발현의 조절
US10221414B2 (en) * 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
EA036496B1 (ru) * 2014-05-01 2020-11-17 Ионис Фармасьютикалз, Инк. Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171066A3 (de) 1984-08-09 1989-02-01 Siemens Aktiengesellschaft Verfahren und Schaltungsanordnung zum Adressieren von Signalabgabe-/Signalaufnahmeeinrichtungen von einer zentralen Verarbeitungseinrichtung her
DE59108644D1 (de) 1990-07-02 1997-05-07 Hoechst Ag Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
KR930016437A (ko) 1992-01-22 1993-08-26 귀틀라인, 슈미트 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도
US6033909A (en) 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
EP0593901B2 (de) 1992-09-24 2008-04-09 Sanofi-Aventis Deutschland GmbH Oligoribonucleotid- und Ribozym-Analoga mit terminalen 3'-3'-bzw.5'-5'-Verknüpfungen
GB9311113D0 (en) * 1993-05-28 1993-07-14 Medical Res Council Probes
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE4408528A1 (de) 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
DE4415370A1 (de) 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE4438918A1 (de) 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
ATE206131T1 (de) 1995-03-13 2001-10-15 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, verfahren zu ihrer herstellung und ihre verwendung
US6309821B1 (en) * 1996-05-16 2001-10-30 Incyte Genomics, Inc. DNA encoding a PAC10 human homolog
EP1066382A1 (en) * 1997-07-23 2001-01-10 Brigham & Women's Hospital, Inc. Lens epithelial cell derived growth factor
JP2002519000A (ja) * 1998-01-28 2002-07-02 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物ｉｉ

Also Published As

Publication number Publication date
HUP0202794A2 (en) 2003-03-28
CN1367828A (zh) 2002-09-04
AR024953A1 (es) 2002-10-30
KR20020033744A (ko) 2002-05-07
SK1162002A3 (en) 2002-06-04
DE19935303A1 (de) 2001-02-08
US6472521B1 (en) 2002-10-29
HUP0202794A3 (en) 2006-03-28
WO2001007602A3 (de) 2001-05-17
IL147541A0 (en) 2002-08-14
NZ516839A (en) 2004-04-30
WO2001007602A2 (de) 2001-02-01
NO20020365L (no) 2002-03-25
MXPA02000817A (es) 2002-07-30
HK1048337A1 (en) 2003-03-28
CN1165617C (zh) 2004-09-08
YU91901A (sh) 2003-02-28
RU2249458C2 (ru) 2005-04-10
PL353733A1 (en) 2003-12-01
CZ2002324A3 (cs) 2002-05-15
CA2380192A1 (en) 2001-02-01
EP1204742A2 (de) 2002-05-15
JP2003505080A (ja) 2003-02-12
HK1048337B (zh) 2005-02-25
EE200200044A (et) 2003-06-16
NO20020365D0 (no) 2002-01-23
AU6568200A (en) 2001-02-13
HRP20020075A2 (en) 2005-10-31
BR0013180A (pt) 2002-04-09
ZA200200655B (en) 2003-09-23

Similar Documents

Publication Publication Date Title
TR200200201T2 (tr) İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler.
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERINEXPRESSION
ATE300613T1 (de) Menschliche, für zyklische nukleotide spezifische phosphodiesterase
MXPA04000179A (es) Oligonucleotidos sinteticos de hebra doble para inhibicion especifica de expresion de gene.
ATE437962T1 (de) Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
ATE190357T1 (de) Schnelles verfahren fur die dns sequenzierung und diagnostische anwendungen
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
DE59609222D1 (de) Amperometrischer Biosensor
DE60021160D1 (de) Protein-deamiderendes Enzym, dafür kodierendes Gen, enzym-produzierendes Mikroorganismus, Verfahren zur Herstellung und Verwendung davon
PT1114033E (pt) 4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas como inibidores de cetp
EP1185546A4 (en) HIGHLY SPECIFIC PRIMERS, EXPRESSION PROCEDURES AND "KIT"
EP0735046A4 (en) OLIGONUCLEOTIDE AND CANCEROSTATIC AGENT THAT CONTAINS THIS AS ACTIVE INGREDIENT
NO983716D0 (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
IT1295970B1 (it) Metodo di sequenziazione di oggetti postali.
BR0210544A (pt) Formação de multiplex de ácido nucleico
DE69939114D1 (de) Nukleinsäuresequenzfamilie und entsprechende proteinsequenzen, die humane endogene retrovirale motive enthalten, und ihre anwendungen
WO1996006949A3 (en) Nucleic acid hybridization assay probes targeted to mycoplasma pneumoniae nucleic acid
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
TR200501541T2 (tr) Leu-hirudinin e.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları
ATE427959T1 (de) Gereinigtes sr-p70 protein
DK1108786T3 (da) Hidtil ukendt kollektin
ATE495268T1 (de) Nukleinsäureamplifizierung und detektion von mykobacterium-spezies